Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics - Summary - MDSpire

Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics

  • By

  • Kai Chen

  • Yongsu Ma

  • Liling Huang

  • Pengfei Wu

  • Heng-Chung Kung

  • Bohan Yang

  • Jixin Zhang

  • Robert A Anders

  • Jacquelyn W Zimmerman

  • Qingfeng Zhu

  • Xiaodong Tian

  • Jin He

  • Yinmo Yang

  • July 1, 2026

  • 0 min

Share

Objective:

To delineate the cancer-associated fibroblast (CAF) landscape in pancreatic ductal adenocarcinoma (PDAC) and explore the relationship between CAF subtypes and clinical outcomes.

Key Findings:
  • Identified a complement-secreting CAF (csCAF) subtype associated with improved overall survival and recurrence-free survival in PDAC patients.
  • Patients with a higher composition of csCAFs exhibited significantly longer survival outcomes.
  • Liver metastasis showed more csCAFs and fewer myofibroblastic CAFs (myCAFs), while lung metastasis was enriched in inflammatory CAFs (iCAFs).
Interpretation:

The study provides insights into the heterogeneity of CAFs in PDAC.

Limitations:
  • The study primarily focuses on a limited number of PDAC specimens, which may not fully represent the broader patient population.
  • Further research is needed to validate the findings and explore the mechanisms driving CAF heterogeneity.
Conclusion:

The findings contribute to the understanding of CAF subtypes in PDAC.

Original Source(s)

Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics

  • by Kai Chen, Yongsu Ma, Liling Huang, Pengfei Wu, Heng-Chung Kung, Bohan Yang, Jixin Zhang, Robert A Anders, Jacquelyn W Zimmerman, Qingfeng Zhu, Xiaodong Tian, Jin He, Yinmo Yang

  • July 1, 2026

Related Content

Treatment patterns and outcomes in patients with multiple myeloma in second relapse in Colombia (freedomm): a multicenter observational study

Impact of RAS mutation status on early progression in patients with initially unresectable colorectal liver metastases undergoing conversion therapy: a retrospective analysis

ERCC6L in human cancers: oncogenic functions, molecular mechanisms, and clinical implications as a prognostic biomarker and therapeutic target